NASDAQ:ANGO AngioDynamics (ANGO) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free ANGO Stock Alerts $6.03 -0.23 (-3.67%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$6.00▼$6.3050-Day Range$5.27▼$7.0352-Week Range$5.26▼$11.38Volume379,009 shsAverage Volume577,230 shsMarket Capitalization$241.53 millionP/E RatioN/ADividend YieldN/APrice Target$14.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get AngioDynamics alerts: Email Address AngioDynamics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside136.3% Upside$14.25 Price TargetShort InterestHealthy5.62% of Shares Sold ShortDividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews Sentiment0.33Based on 2 Articles This WeekInsider TradingAcquiring Shares$67,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.57) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.65 out of 5 starsMedical Sector73rd out of 909 stocksSurgical & Medical Instruments Industry11th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingAngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAngioDynamics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.62% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently decreased by 8.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAngioDynamics has received a 59.93% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ultrasound machines", "Clinical laser systems", and "Intravenous therapy equipment" products. See details.Environmental SustainabilityThe Environmental Impact score for AngioDynamics is -0.99. Previous Next 2.4 News and Social Media Coverage News SentimentAngioDynamics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for AngioDynamics this week, compared to 3 articles on an average week.Search Interest7 people have searched for ANGO on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows3 people have added AngioDynamics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $67,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for AngioDynamics are expected to grow in the coming year, from ($0.57) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About AngioDynamics Stock (NASDAQ:ANGO)AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.Read More ANGO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANGO Stock News HeadlinesApril 9, 2024 | insidertrades.comJames C. Clemmer Acquires 10,000 Shares of AngioDynamics, Inc. (NASDAQ:ANGO) StockApril 21, 2024 | americanbankingnews.comHead to Head Review: Allurion Technologies (NYSE:ALUR) and AngioDynamics (NASDAQ:ANGO)April 24, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”April 17, 2024 | finance.yahoo.comAngioDynamics, Inc. (ANGO) Interactive Stock Chart - Yahoo FinanceApril 17, 2024 | americanbankingnews.comAngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 8.5% in MarchApril 10, 2024 | finance.yahoo.comInsider Spends US$67k Buying More Shares In AngioDynamicsApril 9, 2024 | seekingalpha.comA Leaner AngioDynamics Is A High-Risk Execution-Driven StoryApril 8, 2024 | finance.yahoo.comAngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call TranscriptApril 24, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”April 6, 2024 | finance.yahoo.comAngioDynamics Third Quarter 2024 Earnings: Misses ExpectationsApril 6, 2024 | seekingalpha.comAngioDynamics (ANGO) Q3 2024 Earnings Call TranscriptApril 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth OpportunitiesApril 6, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for AngioDynamics Amidst Strategic Growth and Med-Tech Sector PotentialApril 5, 2024 | msn.comAngioDynamics upgraded at Oppenheimer on pipeline progressApril 4, 2024 | finance.yahoo.comMedical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock SoarsApril 4, 2024 | marketwatch.comAngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 SystemApril 4, 2024 | markets.businessinsider.comANGO Stock Earnings: AngioDynamics Misses EPS, Misses Revenue for Q3 2024April 4, 2024 | marketwatch.comAngioDynamics Gets FDA Clearance For Pulmonary Embolism TreatmentApril 4, 2024 | marketwatch.comAngioDynamics Cut Fiscal-Year Revenue Outlook, Reflecting DivestmentsApril 4, 2024 | sfgate.comAngioDynamics: Fiscal Q3 Earnings SnapshotApril 4, 2024 | markets.businessinsider.comAngioDynamics: FDA Clears AlphaVac F1885 System In Treatment Of Pulmonary EmbolismApril 4, 2024 | markets.businessinsider.comAngioDynamics Q3 Loss Sharply Widens; Slashes FY24 OutlookApril 4, 2024 | msn.comAngioDynamics gets FDA clearance for pulmonary embolism treatment deviceApril 4, 2024 | businesswire.comAngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset DivestitureApril 4, 2024 | businesswire.comAngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PEApril 2, 2024 | msn.comAngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement AgreementApril 2, 2024 | markets.businessinsider.comAngioDynamics Settles All Patent Litigation With C.R. BardSee More Headlines Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/12/2023Today4/24/2024Fiscal Year End5/31/2024Next Earnings (Estimated)7/10/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ANGO CUSIP03475V10 CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees815Year Founded1988Price Target and Rating Average Stock Price Target$14.25 High Stock Price Target$18.00 Low Stock Price Target$10.00 Potential Upside/Downside+136.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,440,000.00 Net Margins-60.21% Pretax Margin-61.53% Return on Equity-3.48% Return on Assets-2.68% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio1.62 Sales & Book Value Annual Sales$324.01 million Price / Sales0.75 Cash Flow$1.06 per share Price / Cash Flow5.71 Book Value$9.64 per share Price / Book0.63Miscellaneous Outstanding Shares40,055,000Free Float38,012,000Market Cap$241.53 million OptionableOptionable Beta0.66 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. James C. Clemmer (Age 60)CEO, President & Director Comp: $982.92kMr. Stephen A. Trowbridge (Age 50)Executive VP & CFO Comp: $528.02kMr. Chad T. Campbell (Age 53)Senior VP and GM of Global Vascular Access & Oncology Global Business Unit Comp: $416.51kMs. Laura Piccinini (Age 55)Senior VP & GM of International Comp: $444.31kMr. Saleem M. CheeksVice President of CommunicationsMr. Benjamin H. Davis (Age 60)Senior Vice President of Business Development Ms. Marna I. Bronfen-Moore (Age 57)Senior Vice President of Human Resources Mr. Warren G. Nighan (Age 55)Senior Vice President of Quality & Regulatory Affairs Comp: $622.11kMs. Kim L. Seabury (Age 57)Senior Vice President of Information Technology Mr. Juan Carlos SernaSenior Vice President of Scientific & Clinical AffairsMore ExecutivesKey CompetitorsAccurayNASDAQ:ARAYSeaSpineNASDAQ:SPNESurmodicsNASDAQ:SRDXCytosorbentsNASDAQ:CTSOOrthofix MedicalNASDAQ:OFIXView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 79,772 shares on 4/18/2024Ownership: 0.018%James C ClemmerBought 10,000 shares on 4/8/2024Total: $67,000.00 ($6.70/share)PNC Financial Services Group Inc.Sold 2,272 shares on 3/22/2024Ownership: 0.037%Fund 1 Investments LLCBought 496,891 shares on 2/15/2024Ownership: 1.247%ADAR1 Capital Management LLCBought 132,962 shares on 2/14/2024Ownership: 0.334%View All Insider TransactionsView All Institutional Transactions ANGO Stock Analysis - Frequently Asked Questions Should I buy or sell AngioDynamics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANGO shares. View ANGO analyst ratings or view top-rated stocks. What is AngioDynamics' stock price target for 2024? 4 equities research analysts have issued twelve-month price objectives for AngioDynamics' stock. Their ANGO share price targets range from $10.00 to $18.00. On average, they anticipate the company's share price to reach $14.25 in the next year. This suggests a possible upside of 136.3% from the stock's current price. View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts. How have ANGO shares performed in 2024? AngioDynamics' stock was trading at $7.84 at the start of the year. Since then, ANGO shares have decreased by 23.1% and is now trading at $6.03. View the best growth stocks for 2024 here. Are investors shorting AngioDynamics? AngioDynamics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 2,250,000 shares, a decrease of 8.5% from the March 15th total of 2,460,000 shares. Based on an average trading volume of 575,400 shares, the days-to-cover ratio is presently 3.9 days. View AngioDynamics' Short Interest. When is AngioDynamics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024. View our ANGO earnings forecast. How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) issued its quarterly earnings data on Wednesday, July, 12th. The medical instruments supplier reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. The medical instruments supplier earned $91.10 million during the quarter, compared to analysts' expectations of $90.73 million. AngioDynamics had a negative net margin of 60.21% and a negative trailing twelve-month return on equity of 3.48%. The business's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.01 EPS. What ETF holds AngioDynamics' stock? Invesco Nasdaq Future Gen 200 ETF holds 7,477 shares of ANGO stock, representing 0.65% of its portfolio. What guidance has AngioDynamics issued on next quarter's earnings? AngioDynamics issued an update on its FY 2024 earnings guidance on Thursday, April, 4th. The company provided EPS guidance of -0.580--0.540 for the period, compared to the consensus estimate of -0.430. The company issued revenue guidance of $270.0 million-$275.0 million, compared to the consensus revenue estimate of $312.1 million. What is James C. Clemmer's approval rating as AngioDynamics' CEO? 34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX). Who are AngioDynamics' major shareholders? AngioDynamics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does AngioDynamics have any subsidiaries? The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.Read More This page (NASDAQ:ANGO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.